Boston Scientific (BSX) 'Surprises' ACC with WATCHMAN Presentation Plans
Tweet
Share
E-mailGet Alerts BSX Hot Sheet
Join SI Premium – FREE
Boston Scientific (NYSE: BSX) said on Monday that is planned to present "acute procedural safety results of the PREVAIL clinical trial that evaluates the WATCHMAN left atrial appendage closure device in patients with nonvalvular atrial fibrillation versus long-term warfarin therapy" at the 62nd Annual Scientific Session of the American College of Cardiology this weekend, a more limited release of data than was expected.
According to reports out Tuesday, the data is currently under review ahead of the presentation this weekend. One spokesperson for the ACoC said, "The release yesterday surprised us. We are investigating with them how much they will present."
WATCHMAN is used to seal off a reservoir in the upper chamber of the heart, where blood could form pools, potentially leading to clots. The study is being conducted to see whether WATCHMAN would be able to prevent strokes.
Shares of Boston Scientific are down 0.5 percent on the session.
According to reports out Tuesday, the data is currently under review ahead of the presentation this weekend. One spokesperson for the ACoC said, "The release yesterday surprised us. We are investigating with them how much they will present."
WATCHMAN is used to seal off a reservoir in the upper chamber of the heart, where blood could form pools, potentially leading to clots. The study is being conducted to see whether WATCHMAN would be able to prevent strokes.
Shares of Boston Scientific are down 0.5 percent on the session.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
- Neurocrine's Ingrezza study shows quality-of-life gains in TD patients
- Eikon picks dose for phase 2/3 melanoma trial of EIK1001
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
